Hepatic nuclear factor 1α inhibiøtor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin

Drug Metabolism and Disposition

Volumn 36, Issue 8, 2008, Pages 1453-1456

  He, Yi Jing ^a,b   Zhang, Wei ^a   Tu, Jiang Hua ^a   Kirchheiner, Julia ^b   Chen, Yao ^a   Guo, Dong ^a   Li, Qing ^a   Li, Zhong Yu ^a   Chen, Hao ^a   Hu, Dong Li ^a   Wang, Dan ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; BILIRUBIN GLUCURONIDE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 1ALPHA INHIBITOR; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1 SUBSTRATE; PLACEBO; ROSUVASTATIN; URSODEOXYCHOLIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BINDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; GENE EXPRESSION REGULATION; GENOTYPE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TRANSCRIPTION REGULATION;

ADULT; AREA UNDER CURVE; BILIRUBIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FLUOROBENZENES; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; MALE; ORGANIC ANION TRANSPORTERS; PROSPECTIVE STUDIES; PYRIMIDINES; SULFONAMIDES; URSODEOXYCHOLIC ACID;

EID: 47949132189     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.020503     Document Type: Article

References (35)

1. Carswell CI, Plosker GL, and Jarvis B (2002) Rosuvastatin. Drugs 62:2075-2085; discussion 2086-2077.
2. Chambaz J, Cardot P, Pastier D, Zannis VI, and Cladaras C (1991) Promoter elements and factors required for hepatic transcription of the human ApoA-II gene. J Biol Chem 266:11676-11685.
3. Cheng X, Maher J, Dieter MZ, and Klaassen CD (2005) Regulation of mouse organic anion-transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways. Drug Metab Dispos 33:1276-1282.
4. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, and Schneck DW (2003a) Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 55:94-99.
5. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, and Schneck DW (2003b) The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 59:51-56.
6. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, and Cantarini MV (2003c) Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 73:322-329.
7. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, and Cantarini MV (2002) The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 58:527-531.
8. Cui Y, Konig J, Leier I, Buchholz U, and Keppler D (2001) Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276:9626-9630.
9. Fajans SS, Bell GI, and Polonsky KS (2001) Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 345:971-980.
10. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, and Kim RB (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793-1806.
11. Huang MJ, Kua KE, Teng HC, Tang KS, Weng HW, and Huang CS (2004) Risk factors for severe hyperbilirubinemia in neonates. Pediatr Res 56:682-689.
12. Ishii Y, Hansen AJ, and Mackenzie PI (2000) Octamer transcription factor-1 enhances hepatic nuclear factor-1alpha-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter. Mol Pharmacol 57:940-947.
13. Jung D, Hagenbuch B, Fried M, Meier PJ, and Kullak-Ublick GA (2004) Role of liver-enriched transcription factors and nuclear receptors in regulating the human, mouse, and rat NTCP gene. Am J Physiol Gastrointest Liver Physiol 286:G752-G761.
14. Jung D, Hagenbuch B, Gresh L, Pontoglio M, Meier PJ, and Kullak-Ublick GA (2001) Characterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1 alpha. J Biol Chem 276:37206-37214.
15. Jung D and Kullak-Ublick GA (2003) Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. Hepatology 37:622-631.
16. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, and Backman JT (2005) Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 78:388-399.
17. Lau YY, Huang Y, Frassetto L, and Benet LZ (2007) effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194-204.
18. Maeda K, Kambara M, Tian Y, Hofmann AF, and Sugiyama Y (2006) Uptake of ursodeoxycholate and its conjugates by human hepatocytes: role of Na(-+)-taurocholate cotransporting polypeptide (NTCP), organic anion transporting polypeptide (OATP) 1B1 (OATP-C), and oatp1B3 (OATP8). Mol Pharm 3:70-77.
19. Maher JM, Slitt AL, Callaghan TN, Cheng X, Cheung C, Gonzalez FJ, and Klaassen CD (2006) Alterations in transporter expression in liver, kidney, and duodenum after targeted disruption of the transcription factor HNF1alpha. Biochem Pharmacol 72:512-522.
20. Martin PD, Kemp J, Dane AL, Warwick MJ, and Schneck DW (2002) No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 42:1352-1357.
21. Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, and Lenz E (2003) Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 25:2822-2835.
22. McTaggart F (2003) Comparative pharmacology of rosuvastatin. Atheroscler Suppl 4:9-14.
23. Mita S, Suzuki H, Akita H, Hayashi H, Onuki R, Hofmann AF, and Sugiyama Y (2006) Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab Dispos 34:1575-1581.
24. Olsson AG, McTaggart F, and Raza A (2002) Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 20:303-328.
25. Ryffel GU (2001) Mutations in the human genes encoding the transcription factors of the hepatocyte nuclear factor (HNF)1 and HNF4 families: functional and pathological consequences. J Mol Endocrinol 27:11-29.
26. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, and Raza A (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75:455-463.
27. Schuster H (2003) Rosuvastatin - a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients. Cardiology 99:126-139.
28. Shitara Y, Hirano M, Sato H, and Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228-236.
29. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, and Schneck DW (2004) Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76:167-177.
30. Trauner M and Boyer JL (2003) Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 83:633-671.
31. Treiber A, Schneiter R, Delahaye S, and Clozel M (2004) Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J Pharmacol Exp Ther 308:1121-1129.
32. Ueno T and Gonzalez FJ (1990) Transcriptional control of the rat hepatic CYP2E1 gene. Mol Cell Biol 10:4495-4505.
33. Vaughan CJ, Gotto AM Jr, and Basson CT (2000) The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35:1-10.
34. Xu LY, He YJ, Zhang W, Deng S, Li Q, Zhang WX, Liu ZQ, Wang D, Huang YF, Zhou HH, et al. (2007) Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients. Acta Pharmacol Sin 28:1693-1697.
35. Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen J, et al. (2006) Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 373:99-103.